Sight Sciences Inc (SGHT) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Sight Sciences Inc $1.11, price $8.53, upside -87.0%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Sight Sciences Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.
How to read this chart
60‑month range $1.29 – $39.10 · fair‑value band $0.7400 – $1.39 · the $8.53 price screens above the $1.11 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 29, 2026.
Follow Sight Sciences in your weekly email
Every Wednesday you see whether Sight Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye.
Show more
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Stock analysis
Sight Sciences Inc (SGHT) currently trades at $8.53, while our model-based Fair Value estimate is $1.11, 87.0% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $0.7400 (bear) to $1.39 (bull), the price of $8.53 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Sight Sciences Inc reported revenue of $77.4M in FY2025 versus $49.0M in FY2021, a compound +12.1%/yr. Reported net income was −$38.4M in FY2025.
Key figures
Market cap $465M · P/S ratio 5.30 · EPS (TTM) $−0.5500 · Net margin −49.7% · Return on equity −48.4% · Return on assets (EBIT) −31.9% · Operating margin −16.6% · Revenue (TTM) $83.4M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 9% below its 52-week high and 167% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −87%, SGHT screens richer than that median.
Fair Value models
Bear $0.7400Fair Value $1.11Bull $1.39
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−3.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.9%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.5%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−116.5% (2020) → −48.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 349 stocks
Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside−87.7% · Bottom 25%
Profitability
Return on assets−10.8% · Bottom 25%
Net margin (TTM)−35.7% · Bottom 25%
Operating margin (TTM)−16.6% · Bottom 25%
Growth and dividend
Revenue growth19.5% · Above median
Balance sheet
Debt / equity0.63× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B7.70× · Priciest 25%
P/S (TTM)5.90× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 9
FUTURE (revenue growth)98· sector 31
PAST (return on equity)0· sector 11
HEALTH (low debt)69· sector 97
DIVIDEND (yield)0· sector 39
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Sight Sciences Inc (SGHT) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of $1.11 versus a price of $8.53, about −87% upside (overvalued).
What is the fair value of SGHT?
Our model-based fair value for Sight Sciences Inc is $1.11 (as of Sep 29, 2026), built from audited fundamentals. The current price: $8.53.
What is the quality score of SGHT?
Sight Sciences Inc has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sight Sciences Inc (SGHT)?
Our model-based price target is the fair value of $1.11 (as of Sep 29, 2026) from 1 valuation models. Cautious scenario $0.7400, optimistic scenario $1.39. It is a calculation from audited fundamentals, not an analyst target.
What is the Sight Sciences Inc stock forecast for 2026?
Our models put fair value at $1.11, about −87% upside versus a price of $8.53 (overvalued). Cautious scenario $0.7400, optimistic scenario $1.39. The calculation is refreshed regularly with new filings.
What is the revenue of Sight Sciences Inc (SGHT)?
Sight Sciences Inc reported trailing-twelve-month revenue of about $83.4M (latest available figure, as of Sep 29, 2026).
What is the intrinsic value of Sight Sciences Inc (SGHT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sight Sciences Inc it is $1.11 per share (as of Sep 29, 2026), against a price of $8.53. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Sight Sciences Inc stock overvalued or undervalued in 2026?
As of Sep 29, 2026, SGHT trades above its calculated fair value: price $8.53, fair value $1.11, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SGHT?
No. The price is what the market pays today ($8.53); the fair value is what the company's own numbers justify ($1.11). For Sight Sciences Inc the two are $7.42 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sight Sciences Inc worth?
The market values Sight Sciences Inc at about $465M (market capitalisation, as of Sep 29, 2026). Per share that is $8.53; our models calculate a fair value of $1.11 per share.
What do the bullish and bearish scenarios say about SGHT?
Our models span a range for Sight Sciences Inc: cautious scenario $0.7400, base $1.11, optimistic $1.39 per share (as of Sep 29, 2026, price $8.53). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sight Sciences Inc (SGHT)?
Balance-sheet figures for Sight Sciences Inc (as of Sep 29, 2026): return on equity −48.4%, debt of 0.63 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is SGHT from its 52-week high?
Sight Sciences Inc trades at $8.53, about 9% below its 52-week high of $9.36 and 167% above the low of $3.20 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $1.11 is for.
Which stocks are comparable to Sight Sciences Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sight Sciences Inc stock attractive at the current price?
The data as of Sep 29, 2026: price $8.53, calculated fair value $1.11 (−87%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SGHT calculated?
We run Sight Sciences Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.11, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Sight Sciences Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sight Sciences Inc (SGHT)?
The closing price on Oct 2, 2026 was $8.53. Our model-based fair value is $1.11, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sight Sciences Inc right now?
The price sits above even our optimistic bull case ($1.39). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($0.7400 to $1.39) leaves room in how you read the outcome.
Key figures of Sight Sciences Inc
How large is the market capitalisation of Sight Sciences Inc (SGHT)?
The market capitalisation of Sight Sciences Inc is $465M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sight Sciences Inc (SGHT)?
The price-to-sales ratio of Sight Sciences Inc is 5.30 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sight Sciences Inc (SGHT)?
Earnings per share at Sight Sciences Inc are $−0.5500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sight Sciences Inc (SGHT)?
The net margin of Sight Sciences Inc is −49.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sight Sciences Inc (SGHT)?
The return on equity (ROE) of Sight Sciences Inc is −48.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sight Sciences Inc (SGHT)?
On an EBIT basis the return on assets of Sight Sciences Inc is −31.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sight Sciences Inc (SGHT)?
The operating margin of Sight Sciences Inc is −16.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sight Sciences Inc (SGHT)?
Revenue at Sight Sciences Inc is growing +19.5% versus a year earlier (3y avg +2.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Sight Sciences Inc (SGHT) generate?
The free cash flow of Sight Sciences Inc is −$29.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sight Sciences Inc (SGHT) hold?
Sight Sciences Inc holds more cash than debt, $51.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Sight Sciences Inc in the live analysis
One click puts Sight Sciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 29, 2026